Get started
Work

Supplementary Table 2 from The MDM2–p53 antagonist BI 907828 in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study

Year: 2024
Type: supplementary-materials
Abstract: Most common any-cause adverse events by highest CTCAE grade with BI 907828 monotherapy
DOI: 10.1158/2159-8290.27025616.v1
Authors: Patricia LoRusso, Noboru Yamamoto, Manish R. Patel, Scott A. Laurie, Todd M. Bauer, Junxian Geng, Teffany Davenport, Michael Teufel, Jian Li, Mehdi Lahmar, Mrinal M. Gounder
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
OpenAlex ID: W4402802774
Cites:
Cited by:
Related to: 10